Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
AssigneeDiamir, LLC
InventorsSamuil R. Umansky, Kira S. Sheinerman
Life of this patent
Estimating the term…
Abstract
Described are methods for detection of neuronal pathologies using quantitative analysis in bodily fluids of synapse and/or neurite small RNAs and application of these methods to early diagnosis and monitoring of neurodegenerative diseases and other neurological disorders.
Claims48
A method for diagnosing a neuronal pathology in a subject, which comprises:
- a. determining the level of at least one synapse or neurite small RNA in a bodily fluid sample from the subject;
- b. comparing the level of the small RNA in the bodily fluid sample from the subject with a control level of the small RNA, and
- c. (i) identifying the subject as being afflicted with the neuronal pathology when the level of the small RNA in the bodily fluid sample from the subject is increased as compared to the control or (ii) identifying the subject as not being afflicted with the neuronal pathology when the level of the small RNA in the bodily fluid sample from the subject is not increased as compared to the control.
A method for diagnosing a neuronal pathology in a subject, which comprises:
- a. determining the level of a synapse or neurite small RNA in a bodily fluid sample from the subject;
- b. determining the level of a neuronal body small RNA in a bodily fluid sample from the subject;
- c. determining the ratio of the levels of the small RNAs determined in steps (a) and (b);
- d. comparing the ratio of the levels of the small RNAs determined in step (c) with a corresponding control ratio, and
- e. (i) identifying the subject as being afflicted with the neuronal pathology when the ratio of the levels of the small RNAs determined in step (c) is higher than the corresponding control ratio or (ii) identifying the subject as not being afflicted with the neuronal pathology when ratio of the levels of the small RNAs determined in step (c) is not higher than the corresponding control ratio.
A method for diagnosing Alzheimer's disease (AD) in a subject, which comprises:
- a. determining the level of at least one synapse or neurite small RNA in a bodily fluid sample from the subject;
- b. comparing the level of the small RNA in the bodily fluid sample from the subject with a control level of the small RNA, and
- c. (i) identifying the subject as being afflicted with AD when the level of the small RNA in the bodily fluid sample from the subject is increased as compared to the control or (ii) identifying the subject as not being afflicted with AD when the level of the small RNA in the bodily fluid sample from the subject is not increased as compared to the control.
A method for diagnosing mild cognitive impairment (MCI) in a subject, which comprises:
- a. determining the level of at least one synapse or neurite small RNA in a bodily fluid sample from the subject;
- b. comparing the level of the small RNA in the bodily fluid sample from the subject with a control level of the small RNA, and
- c. (i) identifying the subject as being afflicted with MCI when the level of the small RNA in the bodily fluid sample from the subject is increased as compared to the control or (ii) identifying the subject as not being afflicted with MCI when the level of the small RNA in the bodily fluid sample from the subject is not increased as compared to the control.
A method for monitoring development of a neuronal pathology in a subject, which comprises:
- a. determining the level of at least one synapse or neurite small RNA in two or more bodily fluid samples from the subject, wherein the samples have been obtained at spaced apart time points, and
- b. comparing the levels of the small RNA between the earlier obtained and later obtained bodily fluid sample(s).
A method for monitoring the effectiveness of a treatment of a neuronal pathology in a subject, which comprises:
- a. determining the level of at least one synapse or neurite small RNA in a bodily fluid sample from the subject obtained prior to initiation of the treatment;
- b. determining the level of the small RNA in one or more bodily fluid sample(s) from the subject obtained in the course of or following the treatment, and
- c. comparing the level of the small RNA determined in steps (a) and (b), and optionally between different samples in step (b).
Dependencies are inferred from the claim text.